Core Points - The company, Maike Bio, announced that it has received a medical device registration certificate from the National Medical Products Administration for its product, the Chlamydia pneumoniae IgG antibody test kit (direct chemiluminescence method) [1] Group 1 - The product is classified as an in vitro diagnostic reagent [1] - The announcement was made on the evening of November 7 [1]

Core Viewpoint - The company, Mike Bio (300463.SZ), has received a medical device registration certificate from the National Medical Products Administration for its pneumonia chlamydia IgG antibody test kit, which is intended for auxiliary diagnosis of pneumonia chlamydia infection [1] Group 1 - The new product is compatible with the company's fully automated chemiluminescence immunoassay analyzers, including the i6000, i3000, i1000, and i800 series [1] - The company has accumulated a total of 140 registered reagent products under the direct chemiluminescence platform to date [1] - The registration of the new product enriches the company's product portfolio, enhancing its overall market competitiveness and positively impacting market expansion and future operations [1]

Core Viewpoint - The company, Maike Bio (300463.SZ), has received a medical device registration certificate from the National Medical Products Administration for its Pneumonia Chlamydia IgG Antibody Test Kit, which enhances its product offerings and market competitiveness [1] Group 1: Product Development - The Pneumonia Chlamydia IgG Antibody Test Kit is a new product developed on the company's direct chemiluminescence platform, aimed at assisting in the diagnosis of Pneumonia Chlamydia infections [1] - The new test kit is compatible with the company's fully automated chemiluminescence immunoassay analyzers, including the i6000, i3000, i1000, and i800 series [1] Group 2: Market Impact - The registration of the new product enriches the company's product portfolio, which now includes a total of 140 registered reagent products under the direct chemiluminescence platform, covering various disease diagnostics such as thyroid function, infectious diseases, cardiac markers, tumor markers, anemia, inflammation, autoimmune diseases, reproductive hormones, and bone metabolism [1] - The introduction of this new product is expected to positively impact the company's market expansion and future operations, enhancing its overall market competitiveness [1]